Navigation Links
Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
Date:5/11/2009

portunities. While at Groundswell Advisors, he served as acting chief executive officer of Unity Pharma, consulted to numerous small biotech companies, and served on the board of directors of Seredigm Corp. Prior to establishing Groundswell, Jay spent ten years at Amgen Inc. where he served in various senior business development roles, including founder and Managing Director of Amgen Ventures, and earlier as head of Corporate Development. His track record includes such notable completed transactions as the acquisitions of Immunex and Tularik as well as numerous other business development efforts totaling over $15 billion in value. Before joining Amgen, Jay spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences.

He received an M.B.A. at Northeastern University and a B.S. in Physiology and Neuroscience from the University of California, San Diego.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify f
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
2. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
3. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
4. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
5. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
6. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
11. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- This report analyzes the worldwide markets for Bioinformatics in ... Biocontent. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:9/16/2014)... Mo. From cell phones to cars and ... life. Scientists and technology companies constantly are seeking ... for the first time using a water-based solution, ... a long-lasting and more efficient nuclear battery that ... a reliable energy source in automobiles and also ...
(Date:9/16/2014)... , Sept. 16, 2014  Donald Fresne, President and ... of Stephan Vagner , PhD to its Scientific Advisory ... of Toulouse, France , performed research at ... , and at Inserm, the French institute of health and ... works both at the Curie Institute, Orsay, France ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 ... initiatives to position themselves for their 89th ... labeling and encoding, Pharma Packaging Solutions is ... hardware and software and new procedures. Establishing ... Good Manufacturing Practices (cGMP), Pharma Packaging Solutions ...
Breaking Biology Technology:Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2
... Q4 2007 sales increased 78.8% compared to Q4 2006 -- ... Estimated sales for FY ... increased 89.4% compared to FY 2006, NEW YORK, March ... a leading provider in the,nutraceutical industry engaged in the development, ...
... WELLESLEY HILLS, Mass., March 5 Joseph F. Finn, ... ActivBiotics, confirmed,today that the sale of ActivBiotics, proprietary assets ... PM on March 14, 2008. There has been,substantial interest ... 48 bid packages being reviewed by companies, in addition,to ...
... NEW YORK, March 5 Bristol-Myers Squibb,Company (NYSE: ... Board of Directors,has elected Jean-Marc Huet senior vice ... In this role, Mr. Huet will be,responsible for ... as the global financial operations of the organization ...
Cached Biology Technology:China Yingxia International Announces Q4 and FY 2007 Estimates 2China Yingxia International Announces Q4 and FY 2007 Estimates 3Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3
(Date:9/16/2014)... . CRG researchers ... Journal of Cell Biology describes how Topo 2 ... , At this very moment thousands of our body,s cells ... the body repairs damaged tissues and regenerates others like skin ... "mitosis", during which the cell duplicates its genetic material and ...
(Date:9/16/2014)... Exxon Valdez spilled 11 million gallons of oil into ... another giant oil spill in the Gulf of Mexico ... Journal of Consumer Research , news coverage of ... of catalyzing changes in the way fossil fuels are ... coverage of these two events helped to resolve many ...
(Date:9/16/2014)... , Sept. 16, 2014  Valencell, Inc., a ... chosen as one of 18 "Showcase Companies" representing ... at the annual CED Tech Venture Conference on September ... Convention Center in Raleigh, North Carolina ... will lead a discussion during the "Digital Health Spotlight ...
Breaking Biology News(10 mins):Unraveling cell division 2Unraveling cell division 3Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2
... 1, 2011 Tiny marine organisms called zooplankton can use ... areas of the ocean where oxygen levels are so low ... trouble as these areas expand due to climate change. ... said University of Rhode Island doctoral student Leanne Elder. "But ...
... 2011 (Bronx, NY) A longstanding medical mystery ... other cognitive problems despite potent antiretroviral therapy may have ... of Yeshiva University. Their findings are published in the June ... Even though antiretroviral treatment suppresses HIV replication and slows ...
... study co-authored by University of Florida researchers provides details on ... concern as warm summer waters attract more people to the ... July print edition of Pacific Science warns that ... may be considered prey. The sharks feed near ...
Cached Biology News:Climate change could turn oxygen-free seas from blessing to curse for zooplankton 2New study documents first cookiecutter shark attack on a live human 2New study documents first cookiecutter shark attack on a live human 3
...
Human Aminopeptidase P1/XPNPEP1 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
streptavidin, Alexa Fluor® 750–allophycocyanin conjugate (Alexa Fluor® 750–allophycocyanin streptavidin) *1 mg/mL*...
AedestaTM Animal Organ/Tissue Perfusion Soln....
Biology Products: